Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems Inc. has experienced significant growth, as evidenced by a 140% increase in Hepzato procedure volume in 2025, indicating greater physician utilization and commercial acceptance. The company has also demonstrated operational efficiency, achieving a year-end cash balance of $91.0 million, a slight increase from $88.9 million at the end of the third quarter, which suggests strong financial management and a solid foundation for future growth. With expectations for salesforce expansion and potential indication expansion on the horizon, Delcath is well-positioned to sustain strong adoption of its Hepzato product and capture a larger share of the market.

Delcath Systems Inc has revised its full-year revenue expectations down to $83M-$85M, a decrease from the previously estimated $93M-$96M, reflecting challenges in achieving new site activations and reduced patient intake. The company's anticipated quarterly gross margins have been adjusted to range between 85-87%, influenced by a significant decline in new patient starts and expected declines in average revenue per kit due to the Medicaid National Drug Rebate Agreement Program. Furthermore, an unexpected slowdown in patient engagement during the summer season, combined with competitive clinical trial activities, has compounded the difficulties faced in realizing projected growth, reinforcing a negative outlook for the firm.